Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Guardant Health ( (GH) ) is now available.
On September 12, 2025, Guardant Health expanded its Board of Directors to 11 members, appointing Alex M. Azar II, former U.S. Secretary of Health and Human Services, as a Class III director. Azar’s extensive experience in both government and the private sector is expected to provide valuable insights as Guardant Health continues to innovate in precision oncology and expand access to its cancer detection and management technologies.
The most recent analyst rating on (GH) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Guardant Health stock, see the GH Stock Forecast page.
Spark’s Take on GH Stock
According to Spark, TipRanks’ AI Analyst, GH is a Neutral.
Guardant Health’s overall stock score is driven by strong technical indicators and a positive earnings call, which highlight significant revenue growth and improved margins. However, financial performance and valuation concerns due to ongoing losses and negative equity weigh down the score.
To see Spark’s full report on GH stock, click here.
More about Guardant Health
Guardant Health is a leading precision oncology company focused on advancing patient care and accelerating new cancer therapies through advanced blood and tissue tests, real-world data, and AI analytics. Founded in 2012, the company aims to improve outcomes across all stages of cancer care, from early detection to monitoring recurrence and selecting treatments for advanced cancer.
Average Trading Volume: 2,487,955
Technical Sentiment Signal: Buy
Current Market Cap: $6.85B
For an in-depth examination of GH stock, go to TipRanks’ Overview page.